NASDAQ:TEM Tempus AI (TEM) Stock Price, News & Analysis $45.88 +0.35 (+0.77%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$45.42 -0.47 (-1.01%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tempus AI Stock (NASDAQ:TEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tempus AI alerts:Sign Up Key Stats Today's Range$44.30▼$45.9350-Day Range$42.37▼$56.7852-Week Range$41.73▼$104.32Volume4.37 million shsAverage Volume6.08 million shsMarket Capitalization$8.24 billionP/E RatioN/ADividend YieldN/APrice Target$68.64Consensus RatingModerate Buy Company Overview Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors. The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data. Through proprietary bioinformatics pipelines and AI algorithms, Tempus delivers interpretive reports that highlight actionable mutations, potential biomarkers and relevant clinical trials. In addition to oncology applications, the platform is designed to support research across immuno-oncology, hematology and other therapeutic areas, helping pharmaceutical and biotechnology partners accelerate drug discovery and development. Founded in 2015 by entrepreneur Eric Lefkofsky, who serves as chairman and chief executive officer, Tempus is headquartered in Chicago with additional laboratory and research facilities across the United States. Under Lefkofsky’s leadership, the company has grown its dataset to include hundreds of thousands of de-identified patient records, establishing one of the industry’s largest repositories of real-world evidence. Tempus collaborates with academic medical centers, regional health systems and community oncology practices to expand access to genomic testing and AI-enabled insights. Through strategic partnerships and a continuous investment in technology, Tempus aims to democratize access to precision medicine and improve patient outcomes on a global scale. Its services are utilized by healthcare providers seeking to tailor treatment plans, by researchers conducting retrospective analyses, and by life sciences organizations pursuing novel therapeutic targets, underscoring Tempus’s role at the intersection of data science and clinical innovation.AI Generated. May Contain Errors. Read More Tempus AI Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreTEM MarketRank™: Tempus AI scored higher than 66% of companies evaluated by MarketBeat, and ranked 285th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingTempus AI has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialTempus AI has a consensus price target of $68.64, representing about 49.6% upside from its current price of $45.88.Amount of Analyst CoverageTempus AI has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tempus AI's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tempus AI are expected to grow in the coming year, from ($1.35) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempus AI is -26.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempus AI is -26.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempus AI has a P/B Ratio of 19.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.77% of the float of Tempus AI has been sold short.Short Interest Ratio / Days to CoverTempus AI has a short interest ratio ("days to cover") of 5.33.Change versus previous monthShort interest in Tempus AI has recently decreased by 3.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTempus AI does not currently pay a dividend.Dividend GrowthTempus AI does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentTempus AI has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tempus AI this week, compared to 11 articles on an average week.Search Interest116 people have searched for TEM on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows28 people have added Tempus AI to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tempus AI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,211,038.00 in company stock.Percentage Held by Insiders24.26% of the stock of Tempus AI is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions24.22% of the stock of Tempus AI is held by institutions.Read more about Tempus AI's insider trading history. Receive TEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempus AI and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEM Stock News HeadlinesTempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use15 minutes ago | businesswire.comAssessing Tempus AI (TEM) Valuation After Recent Share Price WeaknessMay 19 at 6:00 PM | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 21 at 1:00 AM | Weiss Ratings (Ad)How beaten-down Tempus AI stock offers a lottery ticket for traders hereMay 18 at 2:57 PM | msn.comTempus AI And BMS Deepen AI Drug Development Ties As Losses PersistMay 18 at 2:57 PM | finance.yahoo.com7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18 at 7:35 AM | 247wallst.comTempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 15, 2026 | americanbankingnews.comEric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) StockMay 1, 2026 | insidertrades.comSee More Headlines TEM Stock Analysis - Frequently Asked Questions How have TEM shares performed this year? Tempus AI's stock was trading at $59.05 at the start of the year. Since then, TEM stock has decreased by 22.3% and is now trading at $45.88. How were Tempus AI's earnings last quarter? Tempus AI, Inc. (NASDAQ:TEM) posted its earnings results on Tuesday, May, 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The firm's quarterly revenue was up 36.1% compared to the same quarter last year. Read the conference call transcript. When did Tempus AI IPO? Tempus AI (TEM) raised $400 million in an IPO on Wednesday, June 12th 2024. The company issued 11,100,000 shares at a price of $35.00-$37.00 per share. Who are Tempus AI's major shareholders? Top institutional shareholders of Tempus AI include GC Wealth Management RIA LLC (3.70%), Sumitomo Mitsui Trust Group Inc. (2.42%), Amova Asset Management Americas Inc. (2.42%) and Bank of America Corp DE (0.23%). Insiders that own company stock include Bradley A Keywell, Eric P Lefkofsky, Ryan Fukushima, Andrew Polovin, James William Rogers, Erik Phelps, Ryan M Bartolucci, Nadja West, David R Epstein and Jennifer A Doudna. View institutional ownership trends. How do I buy shares of Tempus AI? Shares of TEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tempus AI own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tempus AI investors own include AST SpaceMobile (ASTS), NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), Recursion Pharmaceuticals (RXRX), Genius Sports (GENI) and Super Micro Computer (SMCI). Company Calendar Last Earnings5/05/2026Today5/21/2026AGM 20265/21/2026Investor Day 20265/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TEM's financial health is in the Yellow zone, according to TradeSmith. TEM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryComputer Software Current SymbolNASDAQ:TEM Previous SymbolNASDAQ:TEM CIK1717115 Webwww.tempus.com Phone800-976-5448FaxN/AEmployees3,800Year Founded2015Price Target and Rating Average Price Target for Tempus AI$68.64 High Price Target$100.00 Low Price Target$35.00 Potential Upside/Downside+49.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$245.03 million Net Margins-22.20% Pretax Margin-22.11% Return on Equity-53.83% Return on Assets-11.17% Debt Debt-to-Equity Ratio2.96 Current Ratio3.31 Quick Ratio3.15 Sales & Book Value Annual Sales$1.27 billion Price / Sales6.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book19.78Miscellaneous Outstanding Shares179,570,000Free Float136,003,000Market Cap$8.24 billion OptionableN/A Beta3.99 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TEM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempus AI, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempus AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
